Search Results

AstraZeneca and Bristol-Myers Squibb to Present New Data at American Diabetes Association 73rd Scientific Sessions®

• Authors : By:Media:; Shelly Mittendorf, Bristol-Myers Squibb, 6

• Source: Business Wire, June 14, 2013, 21pp

Record details

AstraZeneca Completes Acquisition of Diabetes Alliance Assets in the U.S. from Bristol-Myers Squibb

• Authors : By:AstraZeneca; Media Contacts; Kristin Rogers, 215-5

• Source: Business Wire, February 3, 2014, 19pp

Record details

Merck Provides Diabetes Portfolio Update and Underscores Comprehensive, Long-Term Commitment to Patients with Diabetes

• Authors : By:Merck; Media:; Pam Eisele, +1 (267) 305-3558

• Source: Business Wire, September 17, 2015, 9pp

Record details

U.S. FDA Approves Once-Daily XIGDUOT XR Tablets for Adults with Type 2 Diabetes

• Authors : By:AstraZeneca; Media:; Esra Erkal-Paler, +44 20 7604

• Source: Business Wire, October 30, 2014, 7pp

Record details

KOMBIGLYZET XR (Saxagliptin and Metformin HCl Extended-Release) Tablets, a New Treatment for Type 2 Diabetes Mellitus in Adults, Now Available in U.S. Pharmacies

• Authors : By:Media: Bristol-Myers Squibb Ken Dominski, 609-252-5251 AstraZeneca Corey Windett, 302-885-0034 Investors: Bristol-Myers Squibb John Elicker, 609-252-4611 AstraZeneca Karl Hard, +44-20-7604-8123

• Source: Business Wire, January 7, 2011, 5pp

Record details

Merck Announces FDA Acceptance of New Drug Application for an Investigational Extended-Release Formulation of JANUMET® (sitagliptin/metformin HCI) for Type 2 Diabetes

• Authors : By:Merck & Co., Inc. Media: Lee Davies, 917-679-6368 Justine O'Malley, 908-423-2021 or Investor: Joseph Romanelli, 908-423-5088

• Source: Business Wire, January 11, 2011, 40pp

Record details

FDA Approves JANUMET(TM) for Type 2 Diabetes, Offering Powerful Glucose Control of a DPP-4 Inhibitor and Metformin in a Single Tablet

• Source: Business Wire, April 2, 2007, 39pp

Record details

Two Merck Medicines Recommended for Approval in the European Union

• Authors : By:Merck & Co. Media: Ron Rogers, 908-423-6449 or Investor: Graeme Bell, 908-423-5185

• Source: Business Wire, April 24, 2008, 92pp

Record details

Merck Provides Diabetes Portfolio Update and Underscores Comprehensive, Long-Term Commitment to Patients with Diabetes.

• Source: Business Wire. 2015.

Record details

AstraZeneca Completes Acquisition of Diabetes Alliance Assets in the U.S. from Bristol-Myers Squibb.

• Source: Business Wire. 2014.

Record details